Supplemental Table 1. Log Rank Analyses for Overall Survival and Progression Free Survival

|  |  |  |  |
| --- | --- | --- | --- |
|  | | p-value | |
| Covariate | | OS | PFS |
| KPS | < 80 | 0.51 | 0.92 |
|  | ≥ 80 |  |  |
|  | Methylated |  |  |
| MGMT | Unmethylated | 0.16 | 0.28 |
|  | N/A |  |  |
|  | GTR |  |  |
| Resection | STR | 0.56 | 0.61 |
|  | Bx |  |  |
| Age | < 75 years | 0.93 | 0.70 |
|  | ≥ 75years |  |  |

Abbreviations: KPS = karnofsky performance score, MGMT = 0-6-methylguanine-DNA-methyltransferase, GTR= gross total resection, STR = sub total resection, Bx = biopsy, OS = overall survival, PFS = progression free survival.

Supplemental Table 2. Treatment Characteristics

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Patient** | **RT Duration**  **(days)** | **PTV1 Volume**  **(cm3)** | **PTV1 Dose**  **(cGy)** | **PTV2 Volume**  **(cm3)** | **PTV2 Dose**  **(cGy)** |
| 1 | 14 | 131.4 | 2,500 | 37.2 | 3400 |
| 2 | 36\* | 463.1 | 2,500 | 144.6 | 3400 |
| 3 | 11 | 396.4 | 3,000 | 175.9 | 3,400 |
| 4 | 11 | 399.5 | 3,000 | 186 | 3,400 |
| 5 | 13 | 257.5 | 3,000 | 50.1 | 3,400 |
| 6 | 14 | 154 | 3,000 | 32.5 | 3,400 |
| 7 | 13 | 677.6 | 3,000 | 260 | 3,400 |
| 8 | 14 | 275.6 | 3,400 | N/A | N/A |
| 9 | 13 | 349.5 | 3,000 | 90.6 | 3,400 |
| 10 | 11 | 546.8 | 3,000 | 254.2 | 3,400 |

Abbreviations: RT = Radiation Therapy, PTV= Planning Target Volume, cm3= cubic centimeters, cGy= centigray, TMZ = temozolomide, \*= patient’s course of RT was lengthened as the patient missed several treatment days secondary to suicidal thoughts.

Supplemental Table 3. Treatment Toxicities

|  |  |
| --- | --- |
| Toxicity | N (%) |
| **Muscle Weakness** |  |
| Grade I | 0 (0.0%) |
| Grade II | 1 (10.0%) |
| Grade III | 0 (0.0%) |
| **Thrombocytopenia** |  |
| Grade I | 1 (10.0%) |
| Grade II | 0 (0.0%) |
| Grade III | 0 (0.0%) |
| **Fatigue** |  |
| Grade I | 2 (20.0%) |
| Grade II | 0 (0.0%) |
| Grade III | 0 (0.0%) |
| **Cognitive Disturbance** |  |
| Grade I | 1 (10.0%) |
| Grade II | 1 (10.0%) |
| Grade III | 0 (0.0%) |
| **Radionecrosis** |  |
| Grade I | 0 (0.0%) |
| Grade II | 0 (0.0%) |
| Grade III | 0 (0.0%) |
| Grade IV | 0 (0.0%) |
| Grade V | 0 (0.0%) |

Based on the Common Terminology Criteria for Adverse Events v 4.00

Supplemental Table 4. Wilcoxon signed-rank test analysis of Quality of Life

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  |  | First | Last | p-value |
| Fact-Br (n = 5) | Median (Q1-Q3) | 140.0 (135.0-158.0) | 162.0 (120.0-170.0) | 1.0000 |
| Time from first to last | Median (Q1-Q3) | 4 months (3 months – 6 months) | |  |

Abbreviations: Fact-BR: Functional Assessment of Cancer Therapy-Brain, Q1: 1st quartile, Q3: 3rd quartile. Please note Quality of Life(QoL) analysis was performed for all patients with QoL data from time of enrollment and at least one non-enrollment (on treatment) set of data (available for 5 patients). First refers to QoL of life performed at enrollment and last refers to the most recent non-enrollment data at time of analysis